Zor Pharmaceuticals

Virulizen is an experimental oncology product that has demonstrated compelling efficacy as well as superior safety in pancreatic cancer patients. The drug has completed a phase III trial in pancreatic cancer, enjoys strong patent protection, and a large market potential in a variety of different cancers.

• Zoticon data mines failed phase III trial and finds clinically meaningful data with a very high statistical significance (P = 0.006) that was missed by licensor


• Zoticon negotiates a successful licensing agreement with Lorus, a publically traded Company in Toronto Canada.


• Zoticon co-authors new patent that has now been issued which extends patent protection to 2030.


• Zoticon puts management in place, including Dr. Steve Glen who had key responsibility for the Gemzar approval, the gold standard for pancreatic cancer.


• Zor raises $8MM in financing as the Company and prepares for a phase III study.

Zoticon finds highly significant data buried in failed phase III trial. Zoticon licenses product, hires top tiered management, authors patent and raises $8MM for confirmatory trial based on this data.